| NKG2D ligands in tumor immunity: two sides of a coin J Zhang, F Basher, JD Wu Frontiers in immunology 6, 97, 2015 | 180 | 2015 |
| Reducing FLI1 levels in the MRL/lpr lupus mouse model impacts T cell function by modulating glycosphingolipid metabolism EM Richard, T Thiyagarajan, MA Bunni, F Basher, PO Roddy, LJ Siskind, ... PloS one 8 (9), e75175, 2013 | 44 | 2013 |
| β-Arrestin 2: a negative regulator of inflammatory responses in polymorphonuclear leukocytes F Basher, H Fan, B Zingarelli, KT Borg, LM Luttrell, GE Tempel, ... International Journal of Clinical and Experimental Medicine 1 (1), 32, 2008 | 42 | 2008 |
| FLI1 levels impact CXCR3 expression and renal infiltration of T cells and renal glycosphingolipid metabolism in the MRL/lpr lupus mouse strain KP Sundararaj, T Thiyagarajan, I Molano, F Basher, TW Powers, ... The Journal of Immunology 195 (12), 5551-5560, 2015 | 30 | 2015 |
| Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy F Basher, P Dhar, X Wang, DA Wainwright, B Zhang, J Sosman, Z Ji, ... Journal of hematology & oncology 13, 1-16, 2020 | 28 | 2020 |
| Cooperative therapeutic anti-tumor effect of IL-15 agonist ALT-803 and co-targeting soluble NKG2D ligand sMIC F Basher, EK Jeng, H Wong, J Wu Oncotarget 7 (1), 814, 2016 | 20 | 2016 |
| Hypogammaglobulinemia and its implications in patients treated with daratumumab: a single institution experience Y Paul, LE Aguirre, F Basher, F Miao, T Koru-Sengul, JE Hoffman Blood 134, 3131, 2019 | 16 | 2019 |
| Tumor-derived NKG2D ligand sMIC reprograms NK cells to an inflammatory phenotype through CBM signalosome activation P Dhar, F Basher, Z Ji, L Huang, S Qin, DA Wainwright, J Robinson, ... Communications Biology 4 (1), 905, 2021 | 10 | 2021 |
| 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one: National Harbor, MD, USA. 9-13 November 2016 A Lundqvist, V van Hoef, X Zhang, E Wennerberg, J Lorent, K Witt, ... Journal for immunotherapy of cancer 4, 1-106, 2016 | 10 | 2016 |
| Executive Summary BL Power, PI Colorado Jan 11, 1-6, 1999 | 9 | 1999 |
| Impact of STK11 and KRAS co-mutations on outcomes with immunotherapy in non-small cell lung cancer. F Basher, D Saravia, D Fanfan, JA Cotta, G Lopes Journal of Clinical Oncology 38 (15_suppl), e15135-e15135, 2020 | 8 | 2020 |
| Aseptic meningitis after recovery from SARS-CoV-2 in an allogeneic stem cell transplant recipient F Basher, JF Camargo, M Diaz-Paez, LJ Lekakis, DL Pereira Clinical Medicine Insights: Case Reports 14, 11795476211009811, 2021 | 4 | 2021 |
| Clinical attributes and outcomes in metastatic non-small cell lung cancer bearing BRAF mutations treated with targeted therapy versus immunotherapy. R Dawar, K Gawri, E Rodriguez, D Kwon, F Basher, PA Costa, K Khan, ... Journal of Clinical Oncology 39 (15_suppl), e21219-e21219, 2021 | 3 | 2021 |
| Heightened TLR7 signaling primes BCR-activated B cells in chronic graft-versus-host disease for effector functions SJ Bracken, AN Suthers, RA DiCioccio, H Su, S Anand, JC Poe, W Jia, ... Blood Advances 8 (3), 667-680, 2024 | 2 | 2024 |
| Genomic classifiers and prognosis of localized prostate cancer: a systematic review MJ Boyer, DJ Carpenter, JR Gingrich, SR Raman, D Sirohi, AA Tabriz, ... Prostate Cancer and Prostatic Diseases, 1-9, 2024 | 2 | 2024 |
| Prevalence of EGFR mutation testing in early-stage lung cancer: Implications of the ADAURA trial for clinical practice. E Rodriguez, R Dawar, F Basher, PA Costa, T Torres, DM Nguyen, ... Journal of Clinical Oncology 39 (15_suppl), e20507-e20507, 2021 | 2 | 2021 |
| Concordance of next-generation sequencing between tissue and liquid biopsies in non-small cell lung cancer. F Basher, D Saravia, D Fanfan, JA Cotta, G Lopes Journal of Clinical Oncology 38 (15_suppl), e21547-e21547, 2020 | 2 | 2020 |
| P2. 06 lung cancer driver mutations and PD-L1 expression in US latino patients with advanced lung cancer D Saravia, F Basher, A Arora, D Soong, D Fanfan, J Cotta, G Lopes Journal of Thoracic Oncology 14 (11), S1187, 2019 | 2 | 2019 |
| MA01. 07 Prognostic Value of STK11 & KRAS Mutations and irAE Incidence in Response to Immunotherapy in Hispanics: A Multicenter Analysis F Basher, L Raez, D Saravia, E Rodriguez, R Uba, A Arora, J Ocejo, ... Journal of Thoracic Oncology 16 (10), S888, 2021 | 1 | 2021 |
| Prognostic value of systemic inflammatory markers in first-and subsequent-line immunotherapy and durability of response in NSCLC. F Basher, D Saravia, G Lopes Journal of Clinical Oncology 39 (15_suppl), e21210-e21210, 2021 | 1 | 2021 |
